1. Market Research
  2. > Pharmaceutical Market Trends
  3. > PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

Summary

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market.

Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Overall, major barriers to the growth of the UC market include -
- Remicade and Humira losing patent protection in the mid-forecast
- Austerity measures favoring generic prescribing
- Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US

Key Questions Answered

- How will the UC market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
- How will the launch of the first-in-class Entyvio change the landscape of the UC market?
- Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
- How will the launch of late-stage pipeline therapies such as etrolizumab and Kappaproct shape the future treatment landscape?
- What are the remaining unmet needs and opportunities for drug developers within the UC market?

Key Findings

- The UC market has predominantly been driven by two TNF blockers, namely J&J’s Remicade and AbbVie’s Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda’s Entyvio and J&J’s Simponi launch in 2014, stealing market share from Humira and Remicade.
- Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion’s Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market.
- During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals’ Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer’s Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis.

Scope

- Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Annualized UC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the UC therapeutics markets.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late stage pipeline drugs.
- Analysis of the current and future market competition in the global UC therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

- Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global UC therapeutics markets.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC therapeutics markets in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global UC therapeutics markets from 2012-2022.
- Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
1 Table of Contents

2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Symptoms 31
3.2.1 Quality of Life 32
4 Epidemiology 33
4.1 Disease Background 33
4.2 Risk Factors and Comorbidities 34
4.2.1 Being Caucasian and Jewish can increase the risk of UC by almost 37 times 35
4.2.2 A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold 35
4.2.3 Current smokers have a lower risk of developing UC than former smokers or never smokers 36
4.3 Global Trends 37
4.3.1 US 38
4.3.2 5EU 40
4.3.3 Japan 43
4.3.4 Canada 44
4.3.5 China 46
4.3.6 India 48
4.4 Forecast Methodology 48
4.4.1 Sources Used 51
4.4.2 Sources Not Used 57
4.4.3 Forecast Assumptions and Methods 57
4.5 Epidemiological Forecast of UC (2012-2022) 63
4.5.1 Incident Cases of UC 63
4.5.2 Age-Specific Incident Cases of UC 65
4.5.3 Sex-Specific Incident Cases of UC 67
4.5.4 Age-Standardized Incidence Rates 68
4.6 Epidemiological Forecast for UC Prevalent Cases (2012-2022) 69
4.6.1 Prevalent Cases of UC 69
4.6.2 Age-Specific Prevalent Cases of UC 71
4.6.3 Sex-Specific Prevalent Cases of UC 73
4.6.4 Age-Standardized Prevalence Rate of UC in All Markets 75
4.7 Discussion 76
4.7.1 Epidemiological Forecast Insight 76
4.7.2 Limitations of the Analysis 77
4.7.3 Strengths of the Analysis 78
5 Disease Management 79
5.1 Diagnosis and Treatment Overview 79
5.1.1 Diagnosis 79
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 82
5.1.3 Clinical Practice 84
5.2 US 87
5.3 France 91
5.4 Germany 93
5.5 Italy 95
5.6 Spain 97
5.7 UK 99
5.8 Japan 101
5.9 Canada 103
5.10 China 105
5.11 India 107
6 Competitive Assessment 109
6.1 Overview 109
6.2 Strategic Competitor Assessment 110
6.3 Product Profiles - Major Brands 111
6.3.1 Remicade (infliximab) 111
6.3.2 Humira (adalimumab) 118
6.3.3 Simponi (golimumab) 124
6.3.4 Entyvio (vedolizumab) 129
6.3.5 Apriso (mesalamine) 138
6.3.6 Asacol HD (mesalamine) 143
6.3.7 Lialda (mesalamine) 148
6.3.8 Pentasa (mesalamine) 152
6.3.9 Colazal (balsazide disodium) 156
6.3.10 Giazo (balsalazide disodium) 159
6.3.11 sfRowasa (mesalamine) 163
6.3.12 Uceris (budesonide) 166
6.3.13 Other Drug Classes Used in the Treatment of UC 170
6.4 Biosimilars 171
6.4.1 Introduction 171
6.4.2 Hospira's Inflectra Versus JandJ's Remicade in Key Autoimmune Diseases 172
6.4.3 Biosimilars in the Immunology Community 172
6.4.4 By the Numbers: Biosimilars in Development 173
6.4.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 175
6.4.6 Biosimilars' Forecast 177
7 Opportunity and Unmet Need 179
7.1 Overview 179
7.2 Unmet Needs 180
7.2.1 Curative Therapy for Severe UC Patients 180
7.2.2 Diagnostic Markers for Disease Severity 180
7.2.3 Personalized Therapy 181
7.2.4 A Replacement for Steroids 181
7.2.5 Novel Oral Drug Formulations 182
7.2.6 Preventative Medicine for Lowering the Associated Colorectal Cancer Risk 183
7.2.7 Improved Management of Infectious Adverse Events 183
7.3 Unmet Needs Gap Analysis 183
7.4 Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools 185
7.5 Predictors of Medically-Refractory Disease 186
8 Pipeline Assessment 187
8.1 Overview 187
8.2 Clinical Trial Mapping 187
8.2.1 Clinical Trials by Country 187
8.3 Clinical Trials by Phase and Trial Status 188
8.4 Promising Drugs in Clinical Development 189
8.4.1 Etrolizumab 191
8.4.2 Xeljanz (tofacitinib) 197
8.4.3 Kappaproct (DIMS 0150) 204
9 Current and Future Players 210
9.1 Overview 210
9.2 Trends in Corporate Strategy 213
9.3 Company Profiles 214
9.3.1 Johnson and Johnson 214
9.3.2 AbbVie 216
9.3.3 Takeda Pharmaceuticals 218
9.3.4 Roche 220
9.3.5 Warner Chilcott 222
9.3.6 Salix Pharmaceuticals/Santarus 223
9.3.7 Shire Pharmaceuticals 225
9.3.8 Ferring Pharmaceuticals 227
9.3.9 Pfizer 229
9.3.10 InDeX Pharmaceuticals 230
10 Market Outlook 233
10.1 Global Markets 233
10.1.1 Forecast 233
10.1.2 Drivers and Barriers - Global Issues 238
10.2 United States 242
10.2.1 Forecast 242
10.2.2 Key Events 247
10.2.3 Drivers and Barriers 247
10.3 France 250
10.3.1 Forecast 250
10.3.2 Key Events 255
10.3.3 Drivers and Barriers 255
10.4 Germany 258
10.4.1 Forecast 258
10.4.2 Key Events 263
10.4.3 Drivers and Barriers 263
10.5 Italy 264
10.5.1 Forecast 264
10.5.2 Key Events 270
10.5.3 Drivers and Barriers 270
10.6 Spain 272
10.6.1 Forecast 272
10.6.2 Key Events 277
10.6.3 Drivers and Barriers 277
10.7 United Kingdom 279
10.7.1 Forecast 279
10.7.2 Key Events 284
10.7.3 Drivers and Barriers 284
10.8 Japan 286
10.8.1 Forecast 286
10.8.2 Key Events 291
10.8.3 Drivers and Barriers 291
10.9 Canada 293
10.9.1 Forecast 293
10.9.2 Key Events 298
10.9.3 Drivers and Barriers 298
10.10 China 300
10.10.1 Forecast 300
10.10.2 Key Events 304
10.10.3 Drivers and Barriers 304
10.11 India 306
10.11.1 Forecast 306
10.11.2 Key Events 310
10.11.3 Drivers and Barriers 310
11 Appendix 313
11.1 Bibliography 313
11.2 Abbreviations 324
11.3 Methodology 329
11.4 Forecasting Methodology 329
11.4.1 Diagnosed UC Patients 329
11.4.2 Percent Drug-Treated Patients 330
11.4.3 Drugs Included in Each Therapeutic Class 330
11.4.4 Launch and Patent Expiry Dates 330
11.4.5 General Pricing Assumptions 331
11.4.6 Individual Drug Assumptions 332
11.4.7 Generic Erosion 334
11.4.8 Pricing of Pipeline Agents 334
11.5 Physicians and Specialists Included in This Study 335
11.6 Primary Research - Prescriber Survey 337
11.7 About the Authors 338
11.7.1 Author 338
11.7.2 Epidemiologist 339
11.7.3 Global Head of Healthcare 339
11.8 About GlobalData 340
11.9 Disclaimer 340

1.1 List of Tables

Table 1: Genetic Factors That Confer a Predisposition to UC 29
Table 2: Typical Symptoms of UC 31
Table 3: Strongest Putative Risk Factors for UC 35
Table 4: Prevalence of UC in the US 40
Table 5: Incidence of UC in the 5EU 41
Table 6: Prevalence of UC in the 5EU 42
Table 7: 10MM, Sources of UC Incidence Data Used in the Epidemiological Forecast 49
Table 8: 10MM, Sources of UC Prevalence Data Used in the Epidemiological Forecast 50
Table 9: 10MM, Incident Cases of UC, Ages ?10 Years, Both Sexes, N, Select Years, 2012-2022 64
Table 10: 10MM, Incident Cases of UC, By Age, Both Sexes, N (Row %), 2012 66
Table 11: 10MM, Incident Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 67
Table 12: 10MM, Prevalent Cases of UC, Ages ?10 Years, Both Sexes, N, Select Years, 2012-2022 70
Table 13: 10MM, Prevalent Cases of UC, By Age, Both Sexes, N (Row %), 2012 72
Table 14: 10MM, Prevalent Cases of UC, By Sex, Ages ?10 Years, N (Row %), 2012 74
Table 15: Truelove and Witts UC Severity Index 81
Table 16: UCDAI 82
Table 17: Treatment Guidelines for UC Used in the 10MM 83
Table 18: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 84
Table 19: UC Management Country Profile - US 90
Table 20: UC Management Country Profile - France 92
Table 21: UC Management Country Profile - Germany 94
Table 22: UC Management Country Profile - Italy 96
Table 23: UC Management Country Profile - Spain 98
Table 24: UC Management Country Profile - UK 100
Table 25: UC Management Country Profile - Japan 102
Table 26: Country Profile - Canada 104
Table 27: UC Management Country Profile - China 106
Table 28: UC Management Country Profile - India 108
Table 29: Leading Treatments for UC, 2014 111
Table 30: Product Profile - Remicade 113
Table 31: Remicade SWOT Analysis, 2014 117
Table 32: Global Sales Forecasts ($m) for Remicade, 2012-2022 118
Table 33: Product Profile - Humira 120
Table 34: Humira Efficacy in the ULTRA 2 Trial 121
Table 35: Product Efficacy Comparison - Humira vs. Remicade 121
Table 36: Humira SWOT Analysis, 2014 123
Table 37: Global Sales Forecasts ($m) for Humira, 2012-2022 124
Table 38: Product Profile - Simponi 126
Table 39: Simponi SWOT Analysis, 2014 128
Table 40: Global Sales Forecasts ($m) for Simponi, 2012-2022 129
Table 41: Product Profile - Entyvio 132
Table 42: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC 133
Table 43: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC 134
Table 44: Most Common Adverse Events with Vedolizumab in the GEMINI I Study 135
Table 45: Entyvio SWOT Analysis, 2014 136
Table 46: Global Sales Forecasts ($m) for Entyvio, 2012-2022 138
Table 47: Product Profile - Apriso 140
Table 48: Apriso SWOT Analysis, 2014 142
Table 49: Global Sales Forecasts ($m) for Apriso, 2012-2022 143
Table 50: Product Profile - Asacol HD 144
Table 51: Asacol HD SWOT Analysis, 2014 147
Table 52: Global Sales Forecasts ($m) for Asacol HD, 2012-2022 148
Table 53: Product Profile - Lialda 149
Table 54: Lialda SWOT Analysis, 2014 151
Table 55: Global Sales Forecasts ($m) for Lialda, 2012-2022 152
Table 56: Product Profile - Pentasa 153
Table 57: Pentasa SWOT Analysis, 2014 155
Table 58: Global Sales Forecasts ($m) for Pentasa, 2012-2022 156
Table 59: Product Profile - Colazal 157
Table 60: Colazal SWOT Analysis, 2014 158
Table 61: Global Sales Forecasts ($m) for Colazal, 2012-2022 159
Table 62: Product Profile - Giazo 160
Table 63: Giazo SWOT Analysis, 2014 162
Table 64: Global Sales Forecasts ($m) for Giazo, 2012-2022 163
Table 65: Product Profile - sfRowasa 164
Table 66: sfRowasa SWOT Analysis, 2014 165
Table 67: Global Sales Forecasts ($m) for sfRowasa, 2012-2022 166
Table 68: Product Profile - Uceris 167
Table 69: Uceris SWOT Analysis, 2014 169
Table 70: Global Sales Forecasts ($m) for Uceris, 2012-2022 170
Table 71: Summary of Other Immunomodulators for UC, 2013 171
Table 72: Biosimilars Pipeline, 2014 174
Table 73: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2012-2022 177
Table 74: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2012-2022 177
Table 75: Global Sales Forecasts ($m) for Golimumab Biosimilars, 2012-2022 178
Table 76: Overall Unmet Needs - Current Level of Attainment 179
Table 77: Corticosteroid Long-Term Side Effects 182
Table 78: Clinical Unmet Needs in UC - Gap Analysis, 2013 184
Table 79: Prognostic Markers in UC 185
Table 80: UC - Clinical Trials by Phase and Status, 2014 189
Table 81: UC - Pre-Registration and Phase III Pipeline, 2014 189
Table 82: Comparison of Therapeutic Classes in Development for UC, 2014 190
Table 83: Product Profile - Etrolizumab 191
Table 84: Results of Phase IIa Trial of Etrolizumab in the Induction of Remission in UC 192
Table 85: Most Common Adverse Events in the Phase IIa Trial of etrolizumab 194
Table 86: Etrolizumab SWOT Analysis, 2014 196
Table 87: Global Sales Forecasts ($m) for Etrolizumab, 2012-2022 197
Table 88: Product Profile - Xeljanz 198
Table 89: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC 199
Table 90: Most Common Adverse Events in the Phase IIa Trial of Xeljanz 201
Table 91: Xeljanz SWOT Analysis, 2014 203
Table 92: Global Sales Forecasts ($m) for Xeljanz, 2012-2022 204
Table 93: Product Profile - Kappaproct 205
Table 94: Results of Phase IIb Trial of Kappaproct in the Induction of Remission in UC 206
Table 95: Kappaproct SWOT Analysis, 2014 208
Table 96: Global Sales Forecasts ($m) for Kappaproct, 2012-2022 209
Table 97: Key Companies in the UC Market, 2012-2022 211
Table 98: JandJ's UC Portfolio Assessment, 2014 215
Table 99: JandJ's SWOT Analysis in UC, 2014 216
Table 100: AbbVie's UC Portfolio Assessment, 2014 217
Table 101: AbbVie's UC SWOT Analysis, 2014 218
Table 102: Takeda Pharmaceuticals' UC Portfolio Assessment, 2014 219
Table 103: Takeda's UC SWOT Analysis, 2014 220
Table 104: Roche's UC Portfolio Assessment, 2014 221
Table 105: Roche's UC SWOT Analysis, 2014 221
Table 106: Warner Chilcott's UC Portfolio Assessment, 2014 223
Table 107: Warner Chilcott's UC SWOT Analysis, 2014 223
Table 108: Salix Pharmaceuticals/Santarus UC Portfolio Assessment, 2013 224
Table 109: Salix Pharmaceuticals/Santarus UC SWOT Analysis, 2014 225
Table 110: Shire Pharmaceuticals' UC Portfolio Assessment, 2014 226
Table 111: Shire Pharmaceuticals' UC SWOT Analysis, 2014 227
Table 112: Ferring Pharmaceuticals' UC Portfolio Assessment, 2013 228
Table 113: Ferring Pharmaceutical's UC SWOT Analysis, 2014 228
Table 114: Pfizer's UC Portfolio Assessment, 2014 229
Table 115: Pfizer's UC SWOT Analysis, 2014 230
Table 116: InDeX Pharmaceuticals' UC Portfolio Assessment, 2013 231
Table 117: InDeX Pharmaceuticals' UC SWOT Analysis, 2014 232
Table 118: Global Sales Forecasts ($m) for UC, 2012-2022 235
Table 119: Global UC Market - Drivers and Barriers, 2012-2022 238
Table 120: Sales Forecasts ($m) for UC in the US, 2012-2022 244
Table 121: Key Events Impacting Sales for UC in the US, 2012-2022 247
Table 122: UC Market in the US - Drivers and Barriers, 2012-2022 247
Table 123: Sales Forecasts ($m) for UC in France, 2012-2022 252
Table 124: Key Events Impacting Sales for UC in France, 2012-2022 255
Table 125: UC Market in France - Drivers and Barriers, 2012-2022 255
Table 126: Sales Forecasts ($m) for UC in Germany, 2012-2022 260
Table 127: Key Events Impacting Sales for UC in Germany, 2012-2022 263
Table 128: UC Market in Germany - Drivers and Barriers, 2012-2022 263
Table 129: Sales Forecasts ($) for UC in Italy, 2012-2022 267
Table 130: Key Events Impacting Sales for UC in Italy, 2012-2022 270
Table 131: UC Market in Italy - Drivers and Barriers, 2012-2022 270
Table 132: Sales Forecasts ($m) for UC in Spain, 2012-2022 274
Table 133: Key Events Impacting Sales for UC in Spain, 2012-2022 277
Table 134: UC Market in Spain - Drivers and Barriers, 2012-2022 277
Table 135: Sales Forecasts ($m) for UC in the UK, 2012-2022 281
Table 136: Key Events Impacting Sales for UC in the UK, 2012-2022 284
Table 137: UC Market in the UK - Drivers and Barriers, 2012-2022 284
Table 138: Sales Forecasts ($) for UC in Japan, 2012-2022 288
Table 139: Key Events Impacting Sales for UC in Japan, 2012-2022 291
Table 140: UC Market in Japan - Drivers and Barriers, 2012-2022 291
Table 141: Sales Forecasts ($m) for UC in Canada, 2012-2022 295
Table 142: Key Events Impacting Sales for UC in Canada, 2012-2022 298
Table 143: UC Market in Canada - Drivers and Barriers, 2012-2022 298
Table 144: Sales Forecasts ($) for UC in China, 2012-2022 301
Table 145: Key Events Impacting Sales for UC in China, 2012-2022 304
Table 146: UC Market in China - Drivers and Barriers, 2012-2022 304
Table 147: Sales Forecasts ($) for UC in India, 2012-2022 307
Table 148: Key Events Impacting Sales for UC in India, 2012-2022 310
Table 149: UC Market in India - Drivers and Barriers, 2012-2022 310
Table 150: Key launches for Ulcerative Colitis , 2012-2022 330
Table 151: Key Patent Expiries 331
Table 152: Annual Cost of Therapy for 5-ASAs ($) 334
Table 153: Physicians Surveyed, By Country 337

1.2 List of Figures

Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC 30
Figure 2: Olmsted Country, Minnesota, US, Age- and Sex-Adjusted Incidence of UC, Cases per 100,000 Population, 1940-2000 39
Figure 3: Canada, Incidence and Prevalence of UC, Cases per 100,000 Population, 1990-2001 45
Figure 4: Hong Kong, China, Crude Incidence and Prevalence of UC, Cases per 100,000 Population, 1997-2006 47
Figure 5: 10MM, Incident Cases of UC, Ages ? 10 Years, Both Sexes, N, 2012-2022 65
Figure 6: 10MM, Incident Cases of UC, By Age, Both Sexes, N, 2012 66
Figure 7: 10MM, Incident Cases of UC, By Sex, Ages ?10 Years, N, 2012 68
Figure 8: 10MM, Age-Standardized Incidence of UC, Ages ?10 Years, Both Sexes, Cases per 100,000 Population, 2012 69
Figure 9: 10MM, Prevalent Cases of UC, Ages ?10 Years, Both Sexes, N, 2012-2022 71
Figure 10: 10MM, Prevalent Cases of UC, By Sex, Ages ? 10 Years, N, 2012 73
Figure 11: 10MM, Prevalent Cases of UC, By Sex, Ages ?10 Years, N, 2012 75
Figure 12: 10MM, Age-Standardized Prevalence of UC, Ages ?10 Years, Both Sexes, %, 2012 76
Figure 13: UC Disease Management Flowchart 87
Figure 14: UC Therapeutics - Clinical Trials by Country, 2014 188
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022 190
Figure 16: Company Portfolio Gap Analysis in UC, 2012-2022 212
Figure 17: Global Sales ($m) for UC by Region, 2012-2022 237
Figure 18: Sales for UC in the US by Drug Class, 2012-2022 246
Figure 19: Sales for UC in France by Drug Class, 2012-2022 254
Figure 20: Sales for UC in Germany by Drug Class, 2012-2022 262
Figure 21: Sales for UC in Italy by Drug Class, 2012-2022 269
Figure 22: Sales for UC in Spain by Drug Class, 2012-2022 276
Figure 23: Sales for UC in the UK by Drug Class, 2012-2022 283
Figure 24: Sales for UC in Japan by Drug Class, 2012-2022 290
Figure 25: Sales for UC in Canada by Drug Class, 2012-2022 297
Figure 26: Sales for UC in China by Drug Class, 2012-2022 303
Figure 27: Sales for UC in India by Drug Class, 2012-2022 309

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

North America Insulin Delivery Market Outlook to 2022

North America Insulin Delivery Market Outlook to 2022

  • $ 5995
  • Industry report
  • January 2017
  • by Global Data

North America Insulin Delivery Market Outlook to 2022 Summary GlobalData’s new report, "North America Insulin Delivery Market Outlook to 2022", provides key market data on the North America Insulin Delivery ...

North America Vision Care Market Outlook to 2022

North America Vision Care Market Outlook to 2022

  • $ 5995
  • Industry report
  • December 2016
  • by Global Data

North America Vision Care Market Outlook to 2022 Summary GlobalData’s new report, "North America Vision Care Market Outlook to 2022", provides key market data on the North America Vision Care market. ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.